2023 Fiscal Year Final Research Report
Innovative treatment and and study of aging suppression mechanism with NAD precursors for aging model disease
Project/Area Number |
21K19437
|
Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
Allocation Type | Multi-year Fund |
Review Section |
Medium-sized Section 52:General internal medicine and related fields
|
Research Institution | Chiba University |
Principal Investigator |
Yokote Koutaro 千葉大学, 大学院医学研究院, 教授 (20312944)
|
Co-Investigator(Kenkyū-buntansha) |
越坂 理也 千葉大学, 医学部附属病院, 助教 (30466700)
前澤 善朗 千葉大学, 大学院医学研究院, 講師 (80436443)
|
Project Period (FY) |
2021-07-09 – 2024-03-31
|
Keywords | ウェルナー症候群 / 遺伝的早老症 / NAD / ニコチンアミドリボシド / 動脈硬化 / 下肢潰瘍 / CAVI / 二重盲検無作為化プラセボ対照クロスオーバー試験 |
Outline of Final Research Achievements |
Werner syndrome (WS) is a rare hereditary progeroid syndrome. Nicotinamide adenine dinucleotide (NAD)+ may play a key role in WS disease pathogenesis and NAD+ supplementation may improve the pathogenesis of WS and other age-related diseases. We conducted a double-blind, randomized, crossover, placebo-controlled trial on patients diagnosed with WS to evaluate the safety and efficacy of NAD+ precursors, Nicotinamide riboside (NR). NR 1,000 mg or placebo were self-administered for 26 weeks and then the patients were crossed over into the opposite arm, and the other capsule was administered for another 26 weeks. The primary endpoint was the safety of NR. The secondary endpoints were NAD+ levels in plasma, number and size of skin ulcers, cardio-ankle vascular index (CAVI), and others. No serious adverse event was observed during NR treatment. The CAVI improved, and the heel pad thinning tended to be slower. Therefore, NR may be beneficial for preventing atherosclerosis in those patients.
|
Free Research Field |
糖尿病・代謝・内分泌内科学
|
Academic Significance and Societal Importance of the Research Achievements |
ウェルナー症候群 (WS) 患者に対するニコチンアミドリボシド (NR) による治療は、重篤な有害事象を発生せずに、心足首血管指数 (CAVI) の結果から動脈硬化の有意な改善を示した。NRはWS患者の動脈硬化予防に有用な治療法である可能性がある。 また、このことから、ウェルナー症候群患者のみならず、一般成人や老人における動脈硬化進展予防の可能性も検討しうると考える。
|